Renal Replacement Therapy in Children in Lithuania: Challenges, Trends, and Outcomes

Ernestas Viršilas 1,*, Rimantė Čerkauskienė 1, Jūratė Masalskienė 2, Šarūnas Rudaitis 2, Diana Dobiliene 2 and Augustina Jankauskiene 1

1 Institute of Clinical Medicine, Vilnius University, LT-08406 Vilnius, Lithuania; rimante.cerkauskiene@gmail.com (R.Č.); augustinajankauskiene@yahoo.com (A.J.)
2 Department of Pediatrics, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania; jurate.masalskiene@gmail.com (J.M.); rsarunas@gmail.com (Š.R.); dobdiana@yahoo.com (D.D.)
* Correspondence: ernestas.virsilas@rocketmail.com; Tel.: +370-6078-7438

Received: 27 September 2018; Accepted: 30 October 2018; Published: 2 November 2018

Abstract: Background and Objectives: Pediatric renal replacement therapy (RRT) in Lithuania resumed in 1994 after a 12-year pause in renal transplantation. Management of end stage renal disease (ESRD) has changed, and outcomes have improved over decades. Our aim was to evaluate the dynamics of RRT in Lithuania in the period 1994–2015, describe its distinctive features, and compare our results with other countries. Materials and Methods: Data between 1994 and 2015 were collected from patients under the age of 18 years with ESRD receiving RRT. The data included: Hemodialysis (HD), peritoneal dialysis (PD), transplantation incidence and prevalence, transplant waiting time, dialysis modalities before transplantation, causes of ESRD and gender distribution in transplanted patients, and patient and graft survival. Results: RRT incidence and prevalence maintained an increase up until 2009. Sixty-four transplantations were performed. Juvenile nephronophthisis (25.9%) was the primary cause of ESRD in transplanted children. The transplant waiting time median was 8.0 months. The male to female ratio post-transplantation was 1.02. Patient survival after transplantation at 10 years was 90.0%, while graft survival for living (related) was 77.0% and 51.1% for deceased. Twelve patients died while on RRT. Conclusions: RRT numbers are increasing in Lithuania. HD is the primary treatment of choice before transplantation, with continued low numbers of preemptive transplantation. Patient survival post-transplantation is favorable, though graft survival is less satisfactory.

Keywords: epidemiology; end stage renal disease; renal replacement therapy; children; Lithuania

1. Introduction

Pediatric renal replacement therapy (RRT) in Lithuania resumed in 1994 after a 12-year pause, initially with hemodialysis (HD) for end stage renal disease (ESRD), then transplantation (Tx) in 1996, and the introduction of peritoneal dialysis (PD) in 1998. Management of ESRD has changed, with outcomes improving over the decades since [1]. Each method of RRT has its own advantages and disadvantages, and each is applied according to medical needs and institutional/national preferences [2–4]. According to the European Society of Pediatric Nephrology (ESPN)/European Renal Association-European Dialysis Transplantation Association (ERA-EDTA) Registry (2014), the treatment modality at RRT initiation was as follows: hemodialysis (HD)—41.2%; peritoneal dialysis (PD)—39.5%; pre-emptive transplantation—18.4% [5]. In Japan, PD predominated (61.7%), followed by pre-emptive transplantation (22.3%) and HD (16.0%) [6]. According to the United States’ renal data system, HD is its dominant modality with an increasing trend, while PD is on a steady decline [7]. As most African
countries are unable to afford chronic RRT, there is lack of data and renal registries regarding the modality of choice from this region [8]. A study by Nakamura-Taira et al. [2] showed that professional care and dialysis-free days were considered advantages of HD, while independence, fewer hospital visits, and flexibility were considered benefits of PD. Sayin et al. [3] found no difference in the quality of life between HD, PD, and transplanted patients. Medical and technical aspects of the procedures dominated earlier clinical focus, while now the focus is on the psychosocial impact on the patient [3]. Our aim was to evaluate RRT dynamics in Lithuania over 22 years, describe its distinctive features, and compare our results with other countries.

2. Materials and Methods

All patients <16 years of age receiving RRT between 1 January 1994 and 31 December 2004 and <18 years between 1 January 2005 and 31 December 2015 were analyzed. Data was collected retrospectively using patient medical records from the only two pediatric nephrology centers in Lithuania (Vilnius, Kaunas) providing RRT for the pediatric population. The following parameters were analyzed: age; sex; incidence and prevalence of hemodialysis, peritoneal dialysis and renal transplantation (Tx); causes of ESRD in transplanted children; RRT before Tx; transplant waiting time; mean age at transplantation; sex distribution of transplanted children; patient and graft survival post-transplantation; and number and causes of death for patients requiring RRT. HD, PD, and Tx incidence were presented as absolute numbers per year, and period prevalence was expressed as the average per time period. Incidence and period prevalence were grouped into time periods to reflect dynamics. A five-year moving average was used to illustrate incidence trends. The incidence of children starting RRT was presented as the number of patients per million age-related population (pmarp). Tx waiting times were expressed as a median with interquartile range (IQR). RRT modality, causes of ESRD, and gender distribution were described in percentages. Patient and graft survival analysis was visualized using the Kaplan-Meier estimate. Statistical analysis was performed using SPSS 20.0 version (IBM Corp., Armonk, New York, NY, USA). We obtained a Regional Biomedical Research Ethics Committee approval (No. 158200-18/5-1039-535 and BE–2-62) to conduct this study.

3. Results

PD, HD, and kidney Tx incidence and period prevalence are presented in Figure 1. PD, HD, and Tx incidence trends are shown in Figure 2 with a five-year moving average calculated and visualized to reflect incidence dynamics. A total of 64 kidney transplantations were performed during the time period analyzed. Causes of ESRD in children were divided into three groups: glomerulonephritis and hemolytic uremic syndrome (HUS); hereditary nephropathies; and congenital anomalies of kidney and urinary tract (CAKUT). The dominant cause of ESRD was glomerulonephritis and HUS, followed by hereditary nephropathies; groups and causes of ESRD of transplanted patients are shown in Table 1. Juvenile nephronophthisis was the most frequent cause of ESRD before Tx. Distribution by sex post-Tx was nearly identical—50.7% were male and 49.3% female (M:F 1.02).

During the 22-year study period, the most frequently used treatment modality was HD (72.7%), followed by PD (15.2%) and a combination of HD and PD (9.1%). Preemptive transplantation was only performed in 3.0% of patients. In the combination group, the change in dialysis was sequential for specific reasons: four patients transitioned from PD to HD before transplantation or as a temporary switch due to compromised peritoneum, and one shifted to PD as a preferred method after stabilization. The mean age at transplantation was 12.85 ± 3.28 years. The incident patients receiving different modalities of RRT age distribution were as follows: 18 in the 0–4 years age group, 16 in the 5–9 years age group, 24 in the 10–14 years age group, and 39 in the group over 14 years of age. The number of children starting RRT in relation to per million age-related population is presented in Table 2. The median transplant waiting time was 7.5 months (IQR 3—20.75), ranging from 0.66 months to 106 months. Patient survival rates after transplantation at 1, 5, and 10 years were 96.5%, 90.0%,
and 90.0%, respectively (Figure 3). All living donations were from patient relatives. Survival rates for living-related kidney transplantation (LRKT) at 1, 5, and 10 years were 94.7%, 88.8%, and 77.0%, deceased graft survival rates were 86.2%, 61.7%, and 51.1%, respectively (Figure 4). Twelve patients died while receiving RRT due to sepsis (33.3%), stroke (25.0%), or other reasons (25.0%). Two patients (16.7%) died due to the inability to perform RRT for various reasons.
Table 1. Causes of end stage renal disease (ESRD) in transplanted children.

| GLOMERULONEPHRITIS AND HEMOLYTIC UREMIC SYNDROME | 43.1% |
|-----------------------------------------------|-------|
| Acute tubular necrosis                          | 3.4%  |
| Chronic glomerulonephritis                      | 6.9%  |
| Denys-drash syndrome                            | 3.4%  |
| Diffuse proliferative glomerulonephritis         | 1.7%  |
| Focal segmental glomerulosclerosis              | 8.6%  |
| Frasier syndrome                                | 3.4%  |
| Goodpasture syndrome                            | 3.4%  |
| Hemolytic-uremic syndrome                       | 5.2%  |
| Membranoproliferative glomerulonephritis         | 3.4%  |
| Rapidly progressive glomerulonephritis          | 3.4%  |

| HEREDITARY NEPHROPATIES                          | 39.7% |
|-----------------------------------------------|-------|
| Hereditary nephropathy (undifferentiated)      | 6.9%  |
| Jeune syndrome                                | 1.7%  |
| Juvenile nephronphthisis                       | 25.9% |
| Kidney polycystosis                            | 5.2%  |

| CONGENITAL KIDNEY ANOMALIES                     | 17.2% |
|-----------------------------------------------|-------|
| Bilateral kidney dysplasia                     | 1.7%  |
| Bronchio oto renal syndrome                    | 1.7%  |
| Hydronephrosis (congenital anomalies of kidney and urinary tract (CAKUT)) | 3.4%  |
| Multicystic dysplastic kidney                  | 1.7%  |
| Reflux nephropathy                             | 5.2%  |
| Renal hypoplasia                               | 3.4%  |

Figure 4. Kaplan-Meier curve for living-related kidney transplantation (LRKT) and cadaveric graft survival after transplantation with 95% confidence intervals.
Table 2. Incidence of children starting renal replacement therapy (RRT) presented as per million age-related population (pmarp).

| Year   | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 |
|--------|------|------|------|------|------|------|------|------|------|------|------|
| Tx preemptive pmarp | 0 | 0 | 0 | 1.15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HD pmarp | 4.36 | 0 | 3.39 | 3.45 | 2.35 | 2.39 | 4.88 | 5.01 | 9.12 | 4.08 | 2.84 |
| PD pmarp | 0 | 0 | 0 | 0 | 0 | 2.39 | 2.44 | 1.25 | 1.3 | 0 | 5.68 |

Population 0–16 years

| Year | 1994 | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 |
|------|------|------|------|------|------|------|------|------|------|------|------|
| Tx preemptive pmarp | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.91 |
| HD pmarp | 9.64 | 17.35 | 4.49 | 3.1 | 1.6 | 3.32 | 12.18 | 1.8 | 5.52 | 0 | 5.72 |
| PD pmarp | 0 | 2.89 | 4.49 | 1.55 | 3.2 | 1.66 | 3.48 | 3.59 | 3.68 | 0 | 3.81 |

Population 0–18 years

| Year | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 |
|------|------|------|------|------|------|------|------|------|------|------|------|
| Tx preemptive pmarp | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.91 |
| HD pmarp | 9.64 | 17.35 | 4.49 | 3.1 | 1.6 | 3.32 | 12.18 | 1.8 | 5.52 | 0 | 5.72 |
| PD pmarp | 0 | 2.89 | 4.49 | 1.55 | 3.2 | 1.66 | 3.48 | 3.59 | 3.68 | 0 | 3.81 |

Population 0–18 years

| Year | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 |
|------|------|------|------|------|------|------|------|------|------|------|------|
| Tx preemptive pmarp | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.91 |
| HD pmarp | 9.64 | 17.35 | 4.49 | 3.1 | 1.6 | 3.32 | 12.18 | 1.8 | 5.52 | 0 | 5.72 |
| PD pmarp | 0 | 2.89 | 4.49 | 1.55 | 3.2 | 1.66 | 3.48 | 3.59 | 3.68 | 0 | 3.81 |
4. Discussion

The incidence of HD and PD showed a steady increase until 2007, after which HD rates stabilized and PD showed a tendency to increase. These findings are explained by the increased ESRD prevalence in our country, which might reflect better recognition and diagnostics of ESRD and the availability of the full range of RRT methods. Worldwide, the incidence of chronic kidney disease (CKD) and ESRD have not increased since 2010 [9]. The incidence of transplantation has varied greatly over the years. Kidney transplantation and RRT averages in Lithuania fall behind most Western European countries (Netherlands, UK, Portugal, Spain, France) [10,11]. It should be noted (Chesnaye at al. [11]) that the results are not completely comparable because of age limits for different study groups and follow-up periods. Renal transplantation as a treatment modality is most prominent in countries with a high gross domestic product (GDP) [10,12], but in Lithuania, the incidence of Tx is slightly higher than in other countries with a similar GDP [10]. Transplant waiting times also varied considerably within patients, but the majority received a transplant in less than 20 months, with decreasing waiting time as the years followed. This is similar to waiting times in other countries [10,13,14] and represents a favorable result, considering Lithuania’s GDP. It should also be noted that our country does not practice presumed consent for organ donation. Another peculiarity is our low rate of preemptive transplantation, which might reflect late referral to nephrologists and thus late recognition of ESRD [15]. Even though more positive outcomes are achieved from preemptive kidney Tx [16], it remains underutilized in Lithuania compared to other countries [10,17].

HD was the second most used dialysis modality in Lithuania after Tx. Two factors played a role: firstly, HD was introduced before PD for chronic patients; secondly, HD and PD are not covered equally by Lithuania’s healthcare system, in that PD materials are covered centrally by our Patients Fund, but the procedure itself is not on the approved list for reimbursement by the government, nor is payment for the relevant staff. This makes PD an unfavorable procedure for economic reasons, while the situation is just the opposite for HD. HD is fully funded, with HD centers widely spread throughout Lithuania and easily accessible for patients within a 50-km distance. Therefore, hospitals may be more inclined to perform HD rather than PD for economic reasons, despite its medical benefits [18], especially in younger children.

Juvenile nephronophthisis was the most frequent disease causing ESRD before Tx, an unexplained peculiarity. Glomerulonephritis and HUS were the dominant causes of ESRD in our transplanted patients. Our results differ from other datasets, in which CAKUT was the leading cause of CKD [19,20] and ESRD [21,22] in transplanted children. Recent data from Lithuania shows a changing trend, with CAKUT becoming the more prominent cause of ESRD among children (unpublished data).

Although some European countries report that males receive renal transplantation more often [23] due to a male predisposition for ESRD, we did not find this tendency, as both sexes received equal numbers of transplants [23]. Considering that males are more predisposed to have CAKUT [24], our equal distribution amongst sexes could reflect inadequate recognition of the anomalies.

The outcome of renal transplantation in children has improved over the last several decades [25,26]. The survival of living-related donor transplants was superior to deceased donor transplants for the first 5 years, which is similar to other reports [27–29], but this trend is lost by 10 years as also reported in other studies [26]. Patient survival rates after Tx were comparable to those of other countries [13,21]. Long-term outcome studies have shown that transplant survival is affected by many factors: the impact of donor source; recipient age; diagnoses; pre-operative immunotherapy and induction therapy; and early and late acute rejections in children that affect graft survival. These factors, however, were not within the scope of our study.

Twelve patients requiring RRT died. Of these 12, six were in dialysis and four died after Tx. Infection was the leading cause of death, followed by stroke. The literature demonstrates that patients receiving RRT are more prone to infections [30] due to immune dysregulation, immunosuppression (if Tx), and/or a constant site of infection (PD/HD). Stroke is one of the CKD-related cardiovascular complications and often is exacerbated by dialysis initiation and
insufficient control of hypertension [31]. Our results demonstrated similar tendencies of mortality causes to those reported in other countries, with infection and cardiovascular complications being the leading causes of mortality [32,33]. Two deaths occurred due to an inability to perform RRT. PD could not be continued for a 6-month-old patient because of fungal peritonitis and compromised peritoneum. At that time, we did not have the technical ability to provide HD for infants. The second death was due to damaged vascular access and, subsequently, the inability to perform HD. PD was not an option for social reasons, as the parents refused to perform it at home. Today, both outcomes could be avoided, given improvements in hospital equipment and governmental social policies.

5. Conclusions

In conclusion, RRT has become increasingly prevalent in recent years. As the prevalence of PD has increased, so has the need for change in governmental policy to fund PD procedures. Transplant waiting times are improving and are satisfactory considering Lithuania’s GDP. Patient survival rates are favorable, but graft survival rates demand improvement. There were 12 deaths during the period analyzed, most of which occurred prior to 2004, with the majority influenced by infection and CVD complications.

Author Contributions: Authors contribution: A.J. conceived and designed the study, contributed material, paper writing; E.V. analyzed data and wrote the paper; J.M., R.Ć., Š.R., and D.D. contributed material.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Van Walraven, C.; Manuel, D.G.; Knoll, G. Survival trends in ESRD patients compared with the general population in the United States. *Am. J. Kidney Dis.* 2014, 63, 491–499. [CrossRef] [PubMed]
2. Nakamura-Taira, N.; Muranaka, Y.; Miwa, M.; Kin, S.; Hirai, K. Views of Japanese patients on the advantages and disadvantages of hemodialysis and peritoneal dialysis. *Int. Urol. Nephrol.* 2013, 45, 1145–1158. [CrossRef] [PubMed]
3. Sayin, A.; Mutluay, R.; Sindel, S. Quality of Life in Hemodialysis, Peritoneal Dialysis, and Transplantation Patients. *Transplant. Proc.* 2007, 39, 3047–3053. [CrossRef] [PubMed]
4. Termorshuizen, F.; Korevaar, J.C.; Dekker, F.W.; Van Manen, J.G.; Boeschoten, E.W.; Krediet, R.T. Hemodialysis and peritoneal dialysis: Comparison of adjusted mortality rates according to the duration of dialysis: Analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. *J. Am. Soc. Nephrol.* 2003, 14, 2851–2860. [CrossRef] [PubMed]
5. ESPN/ERA-EDTA. Update on Registry—December 2016. Available online: https://www.espn-reg.org/files/AR2014_Final.pdf (accessed on 21 February 2017).
6. Hattori, M.; Sako, M.; Kaneko, T.; Ashida, A.; Matsunaga, A.; Igarashi, T.; Itami, N.; Ohta, T.; Gotoh, Y.; Satomura, K.; et al. End-stage renal disease in Japanese children: A nationwide survey during 2006–2011. *Clin. Exp. Nephrol.* 2015, 19, 933–938. [CrossRef] [PubMed]
7. Treatment Modalities. U.S. Renal Data System, USRDS 2010 Annual Data Report: *Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States*; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2010.
8. Harambat, J.; Ekulu, P.M. Inequalities in access to pediatric ESRD care: A global health challenge. *Pedin. Nephrol.* 2016, 31, 353–358. [CrossRef] [PubMed]
9. Becherucci, F.; Roperto, R.M.; Materassi, M.; Romagnani, P. Chronic kidney disease in children. *Clin. Kidney J.* 2016, 9, 583–591. [CrossRef] [PubMed]
10. Harambat, J.; Van Stralen, K.J.; Schaefer, F.; Grenda, R.; Jankauskiene, A.; Kostic, M.; Macher, M.A.; Maxwell, H.; Puretic, Z.; Raes, A.; et al. Disparities in policies, practices and rates of pediatric kidney transplantation in Europe. *Am. J. Transplant.* 2013, 13, 2066–2074. [CrossRef] [PubMed]
11. Chesnaye, N.C.; Schaefer, F.; Groothoff, J.W.; Caskey, F.J.; Heaf, J.G.; Kushnirenko, S.; Mauel, R.; Maurer, E.; Merenmies, J.; Shitza, D.; et al. Disparities in treatment rates of paediatric end-stage renal disease across Europe: Insights from the ESPN/ERA-EDTA registry. *Nephrol. Dial. Transplant.* 2015, 30, 1377–1385. [CrossRef] [PubMed]

12. Chesnaye, N.; Bonthuis, M.; Schaefer, F.; Groothoff, J.W.; Verrina, E.; Heaf, J.G.; Jankauskiene, A.; Lukosiene, V.; Molchanova, E.A.; Mota, C.; et al. Demographics of paediatric renal replacement therapy in Europe: A report of the ESPN/ERA-EDTA registry. *Pediatr. Nephrol.* 2014, 29, 2403–2410. [CrossRef]

13. Paediatric Working Group, ANZDATA Annual Report: Chapter 11 Paediatrics. 2014. Available online: http://www.anzdata.org.au/anzdata/AnzdataReport/37thReport/c11_paediatric_print_20150929.pdf (accessed on 17 November 2016).

14. National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases. *United States Renal Data System. 2015USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States;* National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2015; Volume 2, pp. 239–258.

15. Kallab, S.; Bassil, N.; Esposito, L.; Cardeau-Desangles, I.; Rostaing, L.; Kamar, N. Indications for and barriers to preemptive kidney transplantation: A review. *Transplant. Proc.* 2010, 42, 782–784. [CrossRef] [PubMed]

16. Abramowicz, D.; Hazzan, M.; Maggiore, U.; Peruzzi, L.; Cochat, P.; Oberbauer, R.; Haller, M.C.; Van Biesen, W.; Descartes Working Group and the European Renal Best Practice (ERBP) Advisory Board. Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes Working Group and ERBP. *Nephrol. Dial. Transplant.* 2016, 31, 691–697. [CrossRef] [PubMed]

17. Amaral, S.; Sayed, B.A.; Kutner, N.; Patzer, R.E. Preemptive kidney transplantation is associated with survival benefits among pediatric patients with end-stage renal disease. *Kidney Int.* 2016, 90, 1100–1108. [CrossRef] [PubMed]

18. Dalal, P.; Sangha, H.; Chaudhary, K. In Peritoneal Dialysis, Is There Sufficient Evidence to Make “PD First” Therapy? *Int. J. Nephrol.* 2011, 2011, 239515. [CrossRef] [PubMed]

19. Harambat, J.; Van Stralen, K.J.; Kim, J.J.; Tizard, E.J. Epidemiology of chronic kidney disease in children. *Pediatr. Nephrol.* 2012, 27, 363–373. [CrossRef] [PubMed]

20. Warady, B.A.; Chadha, V. Chronic kidney disease in children: The global perspective. *Pediatr. Nephrol.* 2007, 22, 1999–2009. [CrossRef] [PubMed]

21. Holmberg, C.; Jalanko, H. Long-term effects of paediatric kidney transplantation. *Nat. Rev. Nephrol.* 2015, 12, 1–10. [CrossRef] [PubMed]

22. Canadian Institute for Health Information. Canadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Canada, 2004 to 2013. 2014, pp. 1–129. Available online: https://secure.cihi.ca/free_products/2011_CORR_Annual_Report_EN.pdf (accessed on 17 November 2016).

23. Tjaden, L.A.; Noordzij, M.; van Stralen, K.J.; Kuehni, C.E.; Raes, A.; Cornelissen, E.A.; O’Brien, C.; Papachristou, E.; Schaefer, F.; Groothoff, J.W.; et al. ESPN/ERA-EDTA Registry Study Group. Racial Disparities in Access to and Outcomes of Kidney Transplantation in Children, Adolescents, and Young Adults: Results From the ESPN/ERA-EDTA (European Society of Pediatric Nephrology/European Renal Association–European Dialysis and Transplant Association. *Am. J. Kidney Dis.* 2015, 67, 1–9. [CrossRef]

24. Tain, Y.-L.; Luh, H.; Lin, C.-Y.; Hsu, C.-N. Incidence and Risks of Congenital Anomalies of Kidney and Urinary Tract in Newborns: A Population-Based Case-Control Study in Taiwan. *Medicine (Baltimore)* 2016, 95, e2659. [CrossRef] [PubMed]

25. Van Arendonk, K.J.; Boyarsky, B.J.; Orandi, B.J.; James, N.T.; Smith, J.M.; Colombani, P.M.; Segev, D.L. National trends over 25 years in pediatric kidney transplant outcomes. *Pediatrics* 2014, 133, 594–601. [CrossRef] [PubMed]

26. Rees, L.; Shroff, R.; Hutchinson, C.; Fernando, O.N.; Trompeter, R.S. Long-term outcome of paediatric renal transplantation: Follow-up of 300 children from 1973 to 2000. *Nephron Clin. Pract.* 2007, 105. [CrossRef] [PubMed]

27. Lodhi, S.A.; Meier-Kriesche, H.-U. Kidney allograft survival: The long and short of it. *Nephrol. Dial. Transplant.* 2011, 26, 15–17. [CrossRef] [PubMed]
28. Matas, A.J.; Smith, J.M.; Skeans, M.A.; Thompson, B.; Gustafson, S.K.; Stewart, D.E.; Cherikh, W.S.; Wainright, J.L.; Boyle, G.; Snyder, J.J.; et al. OPTN/SRTR 2012 Annual Data Report: Kidney. *Am. J. Transplant.* 2014, 14, 11–44. [CrossRef] [PubMed]

29. Wang, J.H.; Skeans, M.A.; Israni, A.K. Current Status of Kidney Transplant Outcomes: Dying to Survive. *Adv. Chronic Kidney Dis.* 2016, 23, 281–286. [CrossRef] [PubMed]

30. Kato, S.; Chmielewski, M.; Honda, H.; Pecoits-Filho, R.; Matsuo, S.; Yuzawa, Y.; Tranaeus, A.; Stenvinkel, P.; Lindholm, B. Aspects of immune dysfunction in end-stage renal disease. *Clin. J. Am. Soc. Nephrol.* 2008, 3, 1526–1533. [CrossRef] [PubMed]

31. Power, A. Stroke in dialysis and chronic kidney disease. *Blood Purif.* 2014, 36, 179–183. [CrossRef] [PubMed]

32. Rees, L. Long-term outcome after renal transplantation in childhood. *Pediatr. Nephrol.* 2009, 24, 475–484. [CrossRef] [PubMed]

33. Groothoff, J.W.; Gruppen, M.P.; Offringa, M.; Hutten, J.; Lilien, M.R.; Van de Kar, N.J.; Wolff, E.D.; Davin, J.C.; Heymans, H.S. Mortality and causes of death of end-stage renal disease in children: A Dutch cohort study. *Kidney Int.* 2002, 61, 621–629. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).